NBE-002 in Patients With Advanced Solid Tumors

NCT ID: NCT04441099

Last Updated: 2023-09-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-19
• Study Completion Date: 2023-08-14

Brief Summary

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

Conditions

Advanced Solid Tumor; Advanced Cancer; Triple Negative Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose-escalation Cohort (DEC)

Escalating doses of NBE-002 depending on cohort at enrollment.

Group Type: EXPERIMENTAL

NBE-002

Intervention Type: DRUG

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Safety-expansion Cohort (SEC)

Dose to be determined based on DEC.

Group Type: EXPERIMENTAL

NBE-002

Intervention Type: DRUG

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Expansion Cohort 1 (EC1)

Dose to be determined based on DEC and SEC.

Group Type: EXPERIMENTAL

NBE-002

Intervention Type: DRUG

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Expansion Cohort 2 (EC2)

Dose to be determined based on DEC and SEC.

Group Type: EXPERIMENTAL

NBE-002

Intervention Type: DRUG

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Interventions

NBE-002

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent
• Age ≥18 years
• Phase 1, DEC and SEC: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma), who have progressive disease, have undergone systemic therapy for advanced disease, and for whom no standard therapy is available
• Phase 2, EC1: patients with histologically or cytologically confirmed advanced triple-negative breast cancer, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
• Phase 2, EC2: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma) other than TNBC, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
• Availability of pretreatment tumor tissue
• Phase 1, DEC and SEC: at least one measurable or non-measurable lesion as per RECIST v1.1
• Phase 2, EC1 and EC2: at least one measurable lesion as per RECIST v1.1
• Phase 1, DEC and SEC: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
• Phase 2, EC1 and EC2: ECOG performance status of 0 or 1
• Adequate function of bone marrow, liver, kidneys, heart; adequate coagulation profile
• Both male and female patients must agree to use effective contraceptive methods
• Women of child-bearing potential (WCBP) must have a negative serum pregnancy test
• Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

• Prior treatment with any agent targeting ROR1
• Presence of active central nervous system (CNS) metastasis
• Persistent toxicities from previous systemic anti-neoplastic treatments of Grade > 1 (or Grade > 2 for neurotoxicity)
• Systemic anti-neoplastic therapy within five half-lives or four weeks (six weeks for nitrosourea and mitomycin-C), whichever is shorter, prior to first dose of the study drug
• Wide-field radiotherapy within four weeks, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within two weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
• Major surgery within four weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
• Prior allogeneic bone marrow transplantation
• Significant cardiac disease
• History of thromboembolic or cerebrovascular events within six months prior to first dose of the study drug
• Acute and/or clinically significant bacterial, fungal or viral infection
• Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day
• Concurrent participation in another investigational clinical trial
• Pregnant or breast-feeding females
• Other conditions that prevent the patient from giving informed consent or participating in the trial, or that may increase the risk associated with the study participation, or that may interfere with the interpretation of the study results
• Prior history of malignancy other than inclusion diagnosis within three years prior to first dose of the study drug
• Prior treatment with cumulative lifetime dose of anthracycline

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cmed Clinical Services

OTHER

Sponsor Role: collaborator

NBE-Therapeutics AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sarah Cannon Research Institute - TN Oncology

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

NEXT Oncology

San Antonio, Texas, United States

Countries

United States

Other Identifiers

NBE-002-01

Identifier Type: -

Identifier Source: org_study_id